Market Place
Sourcing Support
Equillium is no longer buying Metacrine, citing new cash
27 Dec 2022 //
FIERCEBIOTECH
Metacrine and Equillium Mutually Agree to Terminate Definitive Merger Agreement
23 Dec 2022 //
GLOBENEWSWIRE
Equillium to Acquire Metacrine in All-Stock Transaction
06 Sep 2022 //
BUSINESSWIRE
Metacrine Reports First-Quarter 2022 Results
12 May 2022 //
GLOBENEWSWIRE
Metacrine Reports Fourth-Quarter 2021 Results
30 Mar 2022 //
GLOBENEWSWIRE
Metacrine Announces Executive Leadership Changes
24 Feb 2022 //
GLOBENEWSWIRE
Metacrine lays off 50% of staff, axes more R&D to focus on IBD
11 Feb 2022 //
FIERCEBIOTECH
Metacrine Reports Third-Quarter 2021 Results
11 Nov 2021 //
GLOBENEWSWIRE
Metacrine shares halved as NASH work thrown out
23 Oct 2021 //
MARKETWATCH
Metacrine Reports Interim Results for MET642 Phase 2a Trial inPatients with NASH
21 Oct 2021 //
GLOBENEWSWIRE
Metacrine dips on R&D day with high trading volume
15 Sep 2021 //
SEEKINGALPHA
Metacrine to Present at 2021 Canaccord Genuity Growth Conference
09 Aug 2021 //
GLOBENEWSWIRE
Metacrine to Present at 2021 Canaccord Genuity Growth Conference
09 Aug 2021 //
GLOBENEWSWIRE
Metacrine to Present New Preclinical Data in Inflammatory Bowel Disease at ECCO
06 Jul 2021 //
GLOBENEWSWIRE
Metacrine & Its Partners to Present Data at EASL International Liver Congress
17 Jun 2021 //
GLOBENEWSWIRE
Metacrine to Present New Preclinical Data on MET642 in Inflammatory BD
18 May 2021 //
GLOBENEWSWIRE
Metacrine Achieves Enrollment Target for MET642 Phase 2a Trial Interim Analysis
18 May 2021 //
GLOBENEWSWIRE
Metacrine Accelerates MET409 Clinical Development Milestone and Reports
13 May 2021 //
GLOBENEWSWIRE
Metacrine Accelerates MET409 Clinical Development Milestone
13 May 2021 //
GLOBENEWSWIRE
Metacrine Provides Business Update and Reports Q4 and 2020 Financial Results
18 Mar 2021 //
GLOBENEWSWIRE
Metacrine to Present Final Results from Phase 1 Trial of MET642
11 Mar 2021 //
GLOBENEWSWIRE
Metacrine Initiates Phase 2a Trial of MET642 for the Treatment
09 Mar 2021 //
GLOBENEWSWIRE
Metacrine Announces Publication of MET409 NASH Proof-of-Concept Study
16 Feb 2021 //
GLOBENEWSWIRE
Metacrine Announces FDA Fast Track Designation for MET642 as a Treatment of NASH
19 Jan 2021 //
GLOBENEWSWIRE
Metacrine Presents Positive MET409 Phase 1b Clinical Data in NASH Patients
27 Aug 2020 //
GLOBENEWSWIRE
Metacrine Announces MET409 Receives FDA Fast Track Designation for the of NASH
25 Aug 2020 //
GLOBENEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.